Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Safety and Efficacy of Intraspinal Transplantation of Autologous ADRC in ALS Patients
The goal of our nonrandomized, open label study is to investigate the safety and efficacy of autologous adipose derived mesenchymal regenerative cells (ADRC) transplantation into the individuals with diagnosed amyotrophic lateral sclerosis (ALS). All enrolled patients will have a documented at least 3-months clinical and electrophisiological observation of ALS disease course prior to study enrollment. Each patient will recive 3 injections of ADRC every 3 months: an intraspinal injection followed by 2 subsequent intrathecal infusions. Safety, adverse events and efficacy will be confirmed by clinical, elecrophisiological ( EMG, MUNIX), neuroimmaging and spirometry together with functional (ALSFRS-R) and objective motor assesment (MRC and dynamometer).
Amyotrophic Lateral Sclerosis (ALS) is an incurable disease of unknown etiology that in a
short time leads to significant impairment of motor functions and death. The frequency of ALS
is 4-8/100 000. Mostly it affects people between 40 and 70 years old, but it can occur at a
younger age. Since the symptom onset is most frequently in the fifth or sixth decade, ALS is
a huge economic burden for the society. There are many studies conducted to treat the disease
and prevent it, but currently the medicine offers only one drug that can slow the appearance
of disease symptoms but could not stop the progression. Yet, improvements in medical
management, including nutrition and breathing, regularly increase patient survival - 50% of
affected patients live at least 3 or more years after diagnosis; 20% live 5 years or more;
and up to 10% will survive more than 10 years. The stem-cell-based therapies could be
therefore a new waited strategy for ALS clinical treatment.
Since the clinical course of ALS may vary substantially between patients, we are planning to
qualify them with a primarily established clinical course based on a detailed anamnesis and
clinical assessment. The goal of our nonrandomized, open label study is to investigate the
safety and efficacy of autologous adipose derived mesenchymal regenerative cells (ADRC)
transplantation into the individuals with diagnosed amyotrophic lateral sclerosis. In order
to select a group of 30 ALS patients for the ADRC treatment, approximately 50 ALS patients
will be examined. All patients enrolled will have a documented at least 3-months clinical and
electrophisiological observation of ALS disease course prior to study enrollment. Each
patient will recive 3 injections of ADRC every 3 months: an intraspinal injection followed by
2 subsequent intrathecal infusions. Safety, adverse events and efficacy will be confirmed by
clinical, elecrophisiological ( EMG, MUNIX), neuroimmaging and spirometry together with
functional (ALSFRS-R) and objective motor assesment (MRC and dynamometer).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
| Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
| Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
| Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
| Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
| Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
| Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
| Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
| Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
| Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
| Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
| Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
| Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
| Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
| Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |